Shareholding disclosure

Alllianz SE

Declared position

3.56%

Threshold

Crossed upwards

Timeline

Published

16.01.2009

Transaction

12.01.2009

Transfer date

12.01.2009

Voting rights breakdown

Voting rights acquired3.56%

Voting rights sold0%

Below threshold0%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

TA91F00062

Beneficial owner

Alllianz SE

Declared address

Alllianz SE, 80802 München

Allianz SE took over cominvest Direct shareholders held by the beneficial owner Allianz SE

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

Alllianz SE

Santhera Pharmaceuticals Holding AG16.01.2009TA91F00062

Disclosure summary

Alllianz SE disclosed a holding in Santhera Pharmaceuticals Holding AG on the acquisition side, published by SIX Exchange Regulation on 16.01.2009, at 3.56% of voting rights. Notice category: Single shareholder.

Disclosed position

3.56%

Voting rights acquired

Voting rights acquired3.56%

Voting rights sold0%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

Alllianz SE disclosed a holding in Santhera Pharmaceuticals Holding AG, published on 16.01.2009.

Publication date16.01.2009

Transaction date12.01.2009

Transfer date12.01.2009

Issuing companySanthera Pharmaceuticals Holding AG

Beneficial ownerAlllianz SE

Declared addressAlllianz SE, 80802 München

CategorySingle shareholder

Voting rights acquired3.56%

Voting rights sold0%

Below threshold0%

ExchangeXSWX

Notification IDTA91F00062

Conditions

Allianz SE took over cominvest Direct shareholders held by the beneficial owner Allianz SE

Source: SIX Exchange Regulation · Publication date: 16.01.2009

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open